Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Cited by
Items 301–400 of 476
The functional consequences and prognostic value of dosage sensitivity in ovarian cancer
Yan, Z., Liu, Y., Wei, Y., Zhao, N., Zhang, Q., Wu, C., Chang, Z., & Xu, Y. (2016) · Molecular BioSystems · doi:10.1039/c6mb00625f · Cited by 9
Li, H., Meng, F., Jiang, L., Ren, Y., Qiu, Z., Yu, P., & Peng, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116548 · Cited by 9
Foksiński, M., Zarakowska, E., Gackowski, D., Skonieczna, M., Gajda, K., Hudy, D., Szpila, A., Białkowski, K., Starczak, M., Labejszo, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195819 · Cited by 9
Zheng, C., Wang, P., Zhang, D., Fang, Z., Feng, Y., Chen, J., Chen, J., Fu, Y., Yang, B., Yu, S., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.015 · Cited by 30
“However, cell lines fail to represent the complexity of the original tumor [4, 5], and PDCs are overly simplistic and lack the structural and physiological characteristics of tumor tissue.”
Nguyen, D. A. H., & Quang, M. T. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01533-2 · Cited by 13
“Traditional cell line-based models show significant changes in their characteristics over time, which leads to them becoming less similar to the original tumors from which they were derived [103, 104].”
Patient-Derived Xenograft Tumor Models: Overview and Relevance to IR
Sheth, R. A., Perkons, N. R., Dondossola, E., Subudhi, S. K., Gade, T. P. F., & Tam, A. L. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.01.782 · Cited by 8
Preclinical tumor mouse models for studying esophageal cancer
Mahmoudian, R. A., Farshchian, M., Golyan, F. F., Mahmoudian, P., Alasti, A., Moghimi, V., Maftooh, M., Khazaei, M., Hassanian, S. M., Ferns, G. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104068 · Cited by 9
Salle, H., Pocard, M. D., Lehmann‐Che, J., Bourthoumieu, S., Labrousse, F., Pimpie, C., Lemnos, L., Guichard, J., Froelich, S. C., & Adle‐Biassette, H. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz121 · Cited by 9
Ragusa, D., Makarov, E. M., Britten, O., Moralli, D., Green, C., & Tosi, S. (2019) · Cancer Reports · doi:10.1002/cnr2.1207 · Cited by 8
Tumor-macrophage crosstalk: how to listen
Dey, T. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa023 · Cited by 9
Carvalho, D. M., Temelso, S., Mackay, A. G., Pemberton, H. N., Rogers, R. F., Kessler, K., Izquierdo, E., Bjerke, L. M., Salom, J. F., Clarke, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.29.424674 · Cited by 16
Mouse Models for Head and Neck Squamous Cell Carcinoma
Zhou, J., Liu, C., Amornphimoltham, P., Cheong, S. C., Gutkind, J. S., Chen, Q., & Wang, Z. (2024) · Journal of Dental Research · doi:10.1177/00220345241240997 · Cited by 7
“These cell lines may undergo selection and adaptation in culture, leading to the loss of both heterogeneity and the original characteristics of the tumor (Gillet et al. 2011).”
BackgroundOvercoming resistance in small-cell lung cancer
Hamilton, G., Hochmair, M. J., & Stickler, S. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2388288 · Cited by 9
“It is well-established that cultured cancer cells may bear little or no resemblance phenotypically and in terms of gene expression patterns to cells derived directly from cancers [35,36].”
Yang, S., & Guo, L. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0479-6 · Cited by 7
“In fact, the most commonly used established cancer cell lines have been recently shown no correlation with original clinical samples [26].”
BackgroundWu, C., Horowitz, D. P., Deutsch, I., Rahmati, R., Schecter, J. M., Saqi, A., & Wang, T. J. C. (2015) · Oncology Letters · doi:10.3892/ol.2015.3836 · Cited by 8
“Recent evidence suggests that immortalized cell lines from a variety of tumor types tend to have gene expressions that are more similar to each other than to their original tissue type (51,52).”
Todaka, A., Umehara, R., Sasaki, K., Serizawa, M., Urakami, K., Kusuhara, M., Yamaguchi, K., & Yasui, H. (2017) · Biomedical Research · doi:10.2220/biomedres.38.29 · Cited by 7
“The reasons include redundant oncogenic mutation, heterogeneity of gene alteration, and chromosomal instability (12, 13).”
BackgroundHee, E. X., Wong, M. K., Tan, S. H., Choo, Z., Kuick, C. H., Ling, S., Yong, M. H., Jain, S., Lian, D. W. Q., Ng, E. H. Q., et al. (2020) · Cancer Science · doi:10.1111/cas.14610 · Cited by 9
Abraham, A., Karathedath, S., Varatharajan, S., Markose, P., Chendamarai, E., Jayavelu, A. K., George, B., Srivastava, A., Mathews, V., & Balasubramanian, P. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1821-2 · Cited by 7
Comparing cancer cell lines and tumor samples by genomic profilesPreprint
Sinha, R., Schultz, N. D., & Sander, C. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/028159 · Cited by 8
Predicting clinical drug response from model systems by non-linear subspace-based transfer learningPreprint
Mourragui, S. M. C., Loog, M., Vis, D. J., Moore, K., Manjón, A. G., van de Wiel, M. A., Reinders, M. J. T., & Wessels, L. F. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.177139 · Cited by 8
Shao, F., Huang, X. H., Ma, Z., Li, L., & Qi, C. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117340 · Cited by 6
Luise, M. D., Kurelac, I., Coluccelli, S., Leo, A. D., Bartoszek, E. M., Iorio, M., Grillini, M., Coadǎ, C. A., de Biase, D., Marchio, L., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00941-6 · Cited by 9
Preclinical models for bladder cancer therapy research
Ertl, I. E., Shariat, S. F., Berger, W., & Englinger, B. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001182 · Cited by 6
Effect of X-ray irradiation on expression of organic anion transporting polypeptides
Zhan, K., Yao, J., Huang, J., Zhou, G., Li, W., Chen, L., & Hong, M. (2013) · International Journal of Radiation Biology · doi:10.3109/09553002.2013.784427 · Cited by 6
“…be pointed out that the cancer cells used in our current study are established immortalized cell lines, though they have a better availability and reproducibility (Harmsen et al. 2008) compared with primary cancer cells, they may express different transporter protein profiles (Gillet et al. 2011).”
Oyama, R., Takahashi, M., Kito, F., Sakumoto, M., Shiozawa, K., Qiao, Z., Yoshida, A., Endo, M., Kawai, A., & Kondo, T. (2018) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-018-0258-2 · Cited by 6
“Comprehensive drug response studies using a large-scale cell line bank revealed that the molecular signatures of cell lines can be used to predict the response of treatments (Gillet et al. 2011; Barretina et al. 2012).”
BackgroundRen, F., Zhu, J., Li, K., Cheng, Y., & Zhu, X. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.02.13 · Cited by 6
“While human cancerderived cell lines remain the most broadly used study models for cancer biology and preclinical cancer therapy hypothetical efficacy testing, the reliability of this model remains debatable and their clinical relevance continue to be questioned (26,27).”
BackgroundProteomic Analysis of the Non-genetic Response to Cisplatin in Lung Cancer Cells
Dutra, C. D. S., Martello, C. L., Cadore, N. A., Ferreira, H. B., Zaha, A., & Monteiro, K. M. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10032 · Cited by 5
Chlapek, P., Zitterbart, K., Křen, L., Filipová, L., Štěrba, J., & Veselská, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172552 · Cited by 7
Lim, S. H., Sa, J. K., Lee, D. W., Kim, J.-S., Kim, S. T., Park, S. H., Ku, B., Park, J. O., Park, Y. S., Lim, H.-Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01327 · Cited by 6
“Second, while PDX systems retain the genomic characteristics of the parental tumors in situ, generation of PDX models is often resource- and timeconsuming (12).”
BackgroundEditorial: Patient-derived tumor models for drug development
Sabaawy, H. E., Broggini, M., & Gupta, S. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1243534 · Cited by 6
“However, due to clonal selection and repeated passages under serum-containing medium for years, cell lines tend to have genetic drift from the original tumors (7).”
BackgroundBedewy, W. A., Mohamed, M. S., Abdelhameed, A. M., Elsawy, M. A., Al-Muhur, M., Ashida, N., Abdalla, A. N., Elwaie, T. A., Nagamatsu, T., & Ali, H. I. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2220570 · Cited by 4
“Other genes and markers that are commonly expressed in MCF-7 cells include cytokeratin 18 (CK18), a marker of epithelial cells, and the cell cycle regulator p53, which is frequently mutated in breast cancer 47 .”
Drug Efficacy Recommendation System of Glioblastoma (GBM) Using Deep Learning
Naveed, S., Husnain, M., Samad, A., Ikram, A., Afreen, H., Gilanie, G., & Alsubaie, N. M. (2024) · IEEE Access · doi:10.1109/access.2024.3514912 · Cited by 10
“This research examines how anti-cancer medications affect cancer cell lines and shows how deep learning might improve healthcare, particularly for the treatment of cancer [23].”
Cho, J. H., Kim, J. S., Kim, S. T., Hong, J. Y., Park, J. O., Park, Y. S., Nam, D.-H., Lee, D. W., & Lee, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215080 · Cited by 6
Stulpinas, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89395 · Cited by 9
“Among others, cell line-derived xenografts did not reflect the complexity of tumor heterogeneity and displayed pronounce genomic differences compared to relevant tumor [152, 153].”
BackgroundPatient-derived xenografts in surgical oncology: A short research review
Hernandez, M. C., Leiting, J. L., Joshi, V. B., Yang, L., Leong, H. S., Thomas, R. M., Fleming, J. B., & Truty, M. J. (2020) · Surgery · doi:10.1016/j.surg.2020.07.031 · Cited by 5
In Vitro Three-Dimensional Cell Cultures as Tool for Precision Medicine
Silvestri, A., Schumacher, D., Silvestrov, M., Schäfer, R., Reinhard, C., Hoffmann, J., Boehnke, K., & Regenbrecht, C. R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_14 · Cited by 5
Yehia, R., Portašiková, J. M., Yosef, R. M., Da’adoosh, B., Kádek, A., Man, P., Giladi, M., & Haitin, Y. (2025) · FEBS Journal · doi:10.1111/febs.70181 · Cited by 4
Guo, P., Fang, H., Shi, H., Zhang, J., Song, G., Fan, C., Qiu, X., Lin, X., Shi, W., Feng, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06787-7 · Cited by 5
“Traditional human tumor cell transplantation models have been widely used for drug development, but only one-third of drugs identified through these models have been validated in phase II clinical trials, with most failing in phase III due to the poor predictive ability of animal models [7].”
Trease, C. H., Longman, M. R., Augousti, A. T., Foot, P. J. S., & Pierscionek, B. K. (2016) · Polymer · doi:10.1016/j.polymer.2016.12.032 · Cited by 4
Ex vivo discovery of synergistic drug combinations for hematologic malignancies
Ali, K. A., Shah, R. D., Dhar, A., Myers, N. M., Nguyen, C., Paul, A., Mancuso, J. E., Patterson, A., Brody, J. P., & Heiser, D. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.001 · Cited by 4
“These features are important because drug sensitivity and gene expression pathways for multidrug resistance are different between generated cells and primary samples [13 – 15].”
BackgroundAdvances in the approaches used to repurpose drugs for neuroblastoma
Miera-Maluenda, M., Pérez-Torres, M., Mañas, A., Rubio‐San‐Simón, A., Butjosa-Espín, M., Ruiz-Duran, P., Seoane, J. A., Moreno, L., & Segura, M. F. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2402413 · Cited by 4
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202006089 · Cited by 4
New Oxadiazole/ Benzimidazole Hybrids: Design, Synthesis, and Molecular Docking Studies.
Hagar, F. F., Abbas, S. H., Sayed, A., Abdelhamid, D. S., & Osman, M. S. A. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.190430.1179 · Cited by 4
Collet, B., Avril, T., Aubry, M., Hamlat, A., Reste, P. L., Chiforeanu, D. C., Vauléon, É., Mosser, J., & Quillien, V. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.07.022 · Cited by 4
Cho-Clark, M. J., Sukumar, G., Vidal, N. M., Raiciulescu, S., Oyola, M. G., Olsen, C. H., Mariño‐Ramírez, L., Dalgard, C. L., & Wu, T. J. (2021) · Oncotarget · doi:10.18632/oncotarget.28161 · Cited by 4
“Over the past few decades, cell lines have been frequently used as models to understand cancer biology in tumors [17–20].”
Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects
Lim, S. Y., Aboelnasr, L. S., & El-Bahrawy, M. A. (2025) · Cancers · doi:10.3390/cancers17193239 · Cited by 4
“There is also increasing evidence about the mislabelling, cross-contamination, and secondary genomic alterations that reduce the reliability of these models [5,6].”
Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling
Head, T., & Cady, N. C. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221074293 · Cited by 4
Beelen, N. A., Ehlers, F. A. I., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.05.001 · Cited by 4
NANOEMULSION AS A DRUG DELIVERY SYSTEM OF ANTICANCER DRUG
MAITY, S., & Banerjee, I. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i4.53759 · Cited by 3
“When paclitaxel was administered in conjunction with DHA, there was only a minimal reduction in the levels of P-gp and ABC transporters [113].”
Patient-derived xenograft model: Applications and challenges in liver cancer
Dou, S., Huo, Y., Gao, M., Li, Q., Kou, B., Chai, M., & Liu, X. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003480 · Cited by 5
“[15,16] The PDX model established by transplanting patient tumor tissue or cancer cells into immunocompromised animals [17] preserves the biological characteristics, microenvironment, and heterogeneity of the patient’s original tumor [18–20] as well as the status of viral, bacterial, and other…”
Predicting temozolomide response in low-grade glioma patients with large-scale machine learning
Du, H., Piyawajanusorn, C., Ghislat, G., & Ballester, P. J. (2025) · BMC Methods · doi:10.1186/s44330-025-00046-3 · Cited by 5
Knier, N. N., Dubois, V. P., Chen, Y., Ronald, J. A., & Foster, P. J. (2021) · Journal of Biological Methods · doi:10.14440/jbm.2021.356 · Cited by 3
“While these cell lines have been well characterized, they do not represent the tumour heterogeneity, metastatic behaviours, and histopathology seen clinically, and are unsuitable for evaluating therapies due to their fast progression in vivo (8,9).”
BackgroundH-Alcántara, A., Kourani, O., Marcos‐Jiménez, A., Martínez-Núñez, P., Herranz-Martín, E., Fuentes, P., Toribio, M. L., Muñoz‐Calleja, C., Iglesias, T., & Campanero, M. R. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06923-z · Cited by 4
Patient-Derived Xenografts of Breast Cancer
Marangoni, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_7 · Cited by 6
Schulze, F., Keperscha, B., Appelhans, D., & Rösen‐Wolff, A. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00475 · Cited by 3
Preclinical In Vivo Evaluation of Novel Radiosensitizers by Local Tumor Control Experiments
Schneider, K., Ebert, N., Kurth, I., & Baumann, M. A. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_7 · Cited by 3
Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine
Gardaneh, M. (2017) · Multidisciplinary Cancer Investigation · doi:10.21859/mci-01021 · Cited by 4
“Therefore, cell line-based data often do not match with those obtained from clinical studies [20], a discrepancy that is reflected in different outcomes of transcriptome studies in clinical samples compared to that of established cancer cell lines [21] and is blamed for failure in developing new drugs [22].”
ResultShao, X., Wáng, Y., Lu, X., Hu, Y., Liao, J., Li, J., Chen, X., Yu, Y., Ai, N., Ying, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101748 · Cited by 3
“…differences between cell lines and patient specimens have been reported, especially in cancer research (Domcke et al., 2013; Ertel et al., 2006; Gillet et al., 2011; Li et al., 2014; Sandberg and Ernberg, 2005; Sinha et al., 2017; Stein et al., 2004), emphasizing the great importance in…”
BackgroundPossible Paths and Potential Barriers to Successfully Modeling Drug Resistance
Anderson, A. C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.78 · Cited by 3
Using cell line and patient samples to improve predictions of patient drug responsePreprint
Zhao, C., Li, Y., Safikhani, Z., Haibe‐Kains, B., & Goldenberg, A. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/026534 · Cited by 3
The Dual Role of ABC Transporters in Drug Metabolism and Resistance to Chemotherapy
Gillet, J., Boonen, M., Jadot, M., & Gottesman, M. M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch76 · Cited by 5
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 4
“Although these methods promote rapid tumor growth and survival, they may also lead to significant and irreversible changes in cellular biology [321, 322], thus limiting the predictive value of these models for clinical outcomes [290].”
Valyi‐Nagy, K. (2016) · Elyns Journal of Cancer Research · doi:10.19104/ejcr.2014.103 · Cited by 2
“Accumulation of genetic aberrations in cancer cell lines occurs with increasing number of passages severely limiting their usefulness for personalized medicine [1,2].”
BackgroundPatient-derived tumor models for human nasopharyngeal carcinoma
Zhou, X., Zhao, W., Chen, Y., & Zhang, Z. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.08.007 · Cited by 3
The Application of the Tissue Microarray (TMA) Technology to Analyze Cerebral Organoids
Biunno, I., Paiola, E., & Blasio, P. D. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211025327 · Cited by 3
Bagheri, V., Gholamin, M., Mansouri, A., & Abbaszadegan, M. R. (2022) · Medical Oncology · doi:10.1007/s12032-022-01742-8 · Cited by 2
“However, the development of chemoresistance is one of the most significant obstacles and persistent problems during the effective treatment of cancer [3, 4].”
BackgroundPreclinical Models of Visceral Sarcomas
Costa, A., Gozzellino, L., Nannini, M., Astolfi, A., Pantaleo, M. A., & Pasquinelli, G. (2023) · Biomolecules · doi:10.3390/biom13111624 · Cited by 2
Nano Emulsions: A Novel Targeted Delivery of Cancer Therapeutics
Krishna, G., & Thrimothi, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004748 · Cited by 4
Jiang, L., Meng, F., Qiu, Z., Zhang, K., Ding, Y., Li, H., Ren, Y., Yu, P., & Peng, J. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.01.005 · Cited by 2
Vu, B. T., Le, H. T., Phan, N. L.-C., & Pham, P. V. (2015) · Biomedical Research and Therapy · doi:10.7603/s40730-015-0006-0 · Cited by 2
Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line
Stoczyńska-Fidelus, E., Piaskowski, S., Pawłowska, R., Szybka, M., Peciak, J., Hułas-Bigoszewska, K., Winiecka-Klimek, M., & Rieske, P. (2015) · Oncology Letters · doi:10.3892/ol.2015.3959 · Cited by 2
“This potential genetic heterogeneity displayed by cell lines cultured in vitro has led to certain opposition to the use of cancer cell lines in modern drug testing (1,2).”
BackgroundGraveline, R., Haida, M., Dumont, C., Poulin, D., Poitout‐Belissent, F., Samadfam, R., Kronenberg, S., Regenass-Lechner, F., Prell, R. A., & Piché, M.-S. (2021) · mAbs · doi:10.1080/19420862.2021.1979447 · Cited by 2
Preclinical Experimentation in Oncology
Nimmagadda, S., Shelake, S., & Pomper, M. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-98947-1_33 · Cited by 2
Liu, K., Newbury, P. A., Glicksberg, B. S., Zeng, W. Z., Andrechek, E. R., & Chen, B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/337287 · Cited by 2
“The differences between cell lines and tumors have raised the critical question to what extent cell lines recapitulate the biology of tumor samples 3,4 .”
BackgroundBlack, M. B., Efremenko, A. Y., McMullen, P. D., Barutcu, A. R., & Nong, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.26.550714 · Cited by 2
Ueda, S., Tanaka, T., Hirosuna, K., Miyamoto, S., Murakami, H., Nishie, R., Tsuchihashi, H., Toji, A., Morita, N., Hashida, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031486 · Cited by 2
Pan-Cancer Drug Response Prediction Using Integrative Principal Component Regression
Liu, Q., Li, G., & Baladandayuthapani, V. (2024) · Statistics in Biosciences · doi:10.1007/s12561-024-09451-8 · Cited by 2
“Specifically, from a genomics perspective, cell lines can genetically drift over prolonged culture periods, potentially adopting mutations and traits that render them less representative of the original patient tumors [11].”
Makine Öğrenmesi Modelleri ile Kanser Hücre Hattı–İlaç Etkileşim Tahmini
Mergen, B., & Özcan, G. (2025) · Afyon Kocatepe University Journal of Sciences and Engineering · doi:10.35414/akufemubid.1555642 · Cited by 1
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers
Liu, Y., He, W., Wu, Q. G., Ji, J., Shen, L., Hao, C., Xu, R., Chen, K.-N., Wu, N., Cao, C.-Q., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14845-y · Cited by 1
Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer
Huang, M., Chu, J., Yu, W., Dou, L., Wang, Q., Jiang, F., Wei, M., Cui, X., Zhao, W., Zhou, J., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339416 · Cited by 3
Bera, P., Raju, R., & Das, D. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70258 · Cited by 1
Vu, B. T., Le, H. T., Phan, N. L.-C., & Pham, P. V. (2017) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-981-10-4361-1_153 · Cited by 1
Selective enrichment of CD133+/SOX2+ glioblastoma stem cells via adherent culture
Lv, K., Chen, Z., Zhang, X., Zhang, Q., & Liu, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9154 · Cited by 6
“An increasing number of studies suggested that purified CSCs grown in vitro could be applied for studying the initiation and progression of tumor as well as chemo-or radiotherapy resistance, tumor relapse and testing for new therapeutic drugs (3,5).”
A not so worthless attempt to develop primary culture from breast FNAC/CNB samples!
Goel, S., Dey, P., Dahiya, D., & Bhatia, A. (2021) · Tissue and Cell · doi:10.1016/j.tice.2021.101517 · Cited by 1
Establishment of breast carcinoma cell lines
Mogilenskikh, A. S., & Sazonov, S. V. (2021) · Genes and Cells · doi:10.23868/202104002 · Cited by 3
In Vivo and In Vitro Properties of Ovarian Cancer Cells
Malek, A. V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-547-7_23 · Cited by 1
Mouse Models of Breast Cancer: Deceptions that Reveal the Truth
Couto, J. P., & Bentires‐Alj, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_6 · Cited by 1
Relevance of neuroendocrine tumours models assessed by kinomic profiling
Romano, D. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2019.04.008 · Cited by 1
From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era
Alessandrini, L., Manchi, M., Italia, F., Perin, T., & Canzonieri, V. (2019) · Current clinical pathology · doi:10.1007/978-3-030-04861-7_10 · Cited by 1
Animal Models of Gynecological Cancers
Venkata, P. P., Medina, D., Nirzhor, S. S. R., Sittadjody, S., Kumaran, R., Ramachandran, I., & Subbarayalu, P. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_18-1 · Cited by 1
The Molecular and Biochemical Variations During Cancer Prognosis in Mouse Models
Yodhaanjali, J. R., Dinesan, A., Basalingappa, K. M., & Gopenath, T. S. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_51 · Cited by 1
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
McDermott, M. S. J. (2012) · Dublin City University Open Access Institutional Repository (Dublin City University) · Cited by 1
de Moraes, L. B. D. C. E. A. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2019.tde-07052019-110949 · Cited by 2
Refet-Mollof, E., Chermat, R., Lafontaine, J., Ye, R. Z., Gervais, T., & Wong, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.03.647075 · Cited by 2
Coussens, N. P., & Teicher, B. A. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2551116 · Cited by 1
Lawson, K. A. (2013) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27173 · Cited by 1
Acute myeloid leukemia : apoptotic signalling and gene expression associated with treatment response
Lindberg, M. L. (2013) · Figshare
Targeting Organic Anion Transporting Polypeptides in Cancer to Improve Diagnostics and Therapy
Hays, A. L. (2012) · KU ScholarWorks (The University of Kansas)
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.